Predicting amyloid PET and tau PET stages with plasma biomarkers
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Staging the severity of Alzheimer’s disease pathology using biomarkers is useful for therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face validity; however, this would be more practical with plasma biomarkers. Our objectives were, first, to examine approaches for staging amyloid and tau PET and, second, to examine prediction of amyloid and tau PET stages using plasma biomarkers. Participants (n = 1136) were enrolled in either the Mayo Clinic Study of Aging or the Alzheimer’s Disease Research Center; had a concurrent amyloid PET, tau PET and blood draw; and met clinical criteria for cognitively unimpaired (n = 864), mild cognitive impairment (n = 148) or Alzheimer’s clinical syndrome with dementia (n = 124). The latter two groups were combined into a cognitively impaired group (n = 272). We used multinomial regression models to estimate discrimination [concordance (C) statistics] among three amyloid PET stages (low, intermediate, high), four tau PET stages (Braak 0, 1–2, 3–4, 5–6) and a combined amyloid and tau PET stage (none/low versus intermediate/high severity) using plasma biomarkers as predictors separately within unimpaired and impaired individuals. Plasma analytes, p-tau181, Aβ1–42 and Aβ1–40 (analysed as the Aβ42/Aβ40 ratio), glial fibrillary acidic protein and neurofilament light chain were measured on the HD-X Simoa Quanterix platform. Plasma p-tau217 was also measured in a subset (n = 355) of cognitively unimpaired participants using the Lilly Meso Scale Discovery assay. Models with all Quanterix plasma analytes along with risk factors (age, sex and APOE) most often provided the best discrimination among amyloid PET stages (C = 0.78–0.82). Models with p-tau181 provided similar discrimination of tau PET stages to models with all four plasma analytes (C = 0.72–0.85 versus C = 0.73–0.86). Discriminating a PET proxy of intermediate/high from none/low Alzheimer’s disease neuropathological change with all four Quanterix plasma analytes was excellent but not better than p-tau181 only (C = 0.88 versus 0.87 for unimpaired and C = 0.91 versus 0.90 for impaired). Lilly p-tau217 outperformed the Quanterix p-tau181 assay for discriminating high versus intermediate amyloid (C = 0.85 versus 0.74) but did not improve over a model with all Quanterix plasma analytes and risk factors (C = 0.85 versus 0.83). Plasma analytes along with risk factors can discriminate between amyloid and tau PET stages and between a PET surrogate for intermediate/high versus none/low neuropathological change with accuracy in the acceptable to excellent range. Combinations of plasma analytes are better than single analytes for many staging predictions with the exception that Quanterix p-tau181 alone usually performed equivalently to combinations of Quanterix analytes for tau PET discrimination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Hosmer, D. W., Lemeshow, S., & Sturdivant, R. X. (2013) · Wiley Series in Probability and Statistics · doi:10.1002/9781118548387 · Cited by 13,861
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 1×
“PET stage and dosing modifications during the study were based on amyloid PET stage.(41) Staging the severity of Aβ and tau pathology”
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 1×
“Head-to-head comparisons have shown that individual assays with better diagnostic performance than the Quanterix analytes used in this study exist for both plasma Aβ42/Aβ40 and p-tau.(5,10,21,90,107,108) Modest diagnostic performance is illustrated by the overlap in indi-”
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Research works printed but not linked: 44
- Li, 2007, CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study, Neurology, 69, 631, 10.1212/01.wnl.0000267428.62582.aa · DOI · Paper page
- Karikari, 2021, Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s disease neuroimaging initiative, Mol Psychiatry, 26, 429, 10.1038/s41380-020-00923-z · DOI · Paper page
- Pichet Binette, 2022, Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients, Alzheimers Res Ther, 14, 46, 10.1186/s13195-022-00990-0 · DOI · Paper page
- Janelidze, 2021, Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease, JAMA Neurol, 78, 149, 10.1001/jamaneurol.2020.4201 · DOI · Paper page
- Moscoso, 2021, Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease, JAMA Neurol, 78, 396, 10.1001/jamaneurol.2020.4986 · DOI · Paper page
- Pilotto, 2022, Differences between plasma and cerebrospinal fluid p-tau181 and p-tau231 in early Alzheimer’s disease, J Alzheimers Dis, 87, 991, 10.3233/JAD-215646 · DOI
- Brickman, 2021, Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study, Alzheimers Dement, 17, 1353, 10.1002/alz.12301 · DOI · Paper page
- Morrison, 2022, Antemortem plasma phosphorylated tau (181) predicts Alzheimer’s disease neuropathology and regional tau at autopsy, Brain, 145, 3546, 10.1093/brain/awac175 · DOI
- Smirnov, 2022, Plasma biomarkers for Alzheimer’s disease in relation to neuropathology and cognitive change, Acta Neuropathol, 143, 487, 10.1007/s00401-022-02408-5 · DOI · Paper page
- Mielke, 2019, Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures, Neurology, 93, e252, 10.1212/WNL.0000000000007767 · DOI · Paper page
- Ashton, 2020, An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders, Nat Rev Neurol, 16, 265, 10.1038/s41582-020-0348-0 · DOI · Paper page
- Benedet, 2020, Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease, Brain, 143, 3793, 10.1093/brain/awaa342 · DOI · Paper page
- Verberk, 2021, Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: A prospective memory clinic-based cohort study, Lancet Healthy Longev, 2, e87, 10.1016/S2666-7568(20)30061-1 · DOI · Paper page
- Thijssen, 2022, Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia, Alzheimers Dement (Amst), 14
- O’Connor, 2023, Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: A longitudinal cohort study, J Neurol Neurosurg Psychiatry, 94, 90, 10.1136/jnnp-2022-329663 · DOI
- Sperling, 2014, The A4 study: Stopping AD before symptoms begin?, Sci Transl Med, 6, 10.1126/scitranslmed.3007941 · DOI · Paper page
- Jack, 2022, Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: Hazard ratios and absolute risk, Brain Commun, 4, 10.1093/braincomms/fcac017 · DOI · Paper page
- Collij, 2020, Multitracer model for staging cortical amyloid deposition using PET imaging, Neurology, 95, e1538, 10.1212/WNL.0000000000010256 · DOI · Paper page
- Hanseeuw, 2018, PET staging of amyloidosis using striatum, Alzheimers Dement, 14, 1281, 10.1016/j.jalz.2018.04.011 · DOI · Paper page
- Therriault, 2022, Biomarker modeling of Alzheimer’s disease using PET-based Braak staging, Nature aging, 2, 526, 10.1038/s43587-022-00204-0 · DOI · Paper page
- Schwarz, 2018, Topographic staging of tau positron emission tomography images, Alzheimers Dement (Amst), 10, 221, 10.1016/j.dadm.2018.01.006 · DOI · Paper page
- Wang, 2016, Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy, JAMA Neurol, 73, 1070, 10.1001/jamaneurol.2016.2078 · DOI · Paper page
- Villemagne, 2016, The tau MeTeR scale for the generation of continuous and categorical measures of tau deposits in the brain: Results from 18F-AV1451 and 18F-THK5351 tau imaging studies, Alzheimers Dement., 12, 244, 10.1016/j.jalz.2016.06.437 · DOI
- Roberts, 2008, The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics, Neuroepidemiology, 30, 58, 10.1159/000115751 · DOI · Paper page
- Petersen, 2004, Mild cognitive impairment as a diagnostic entity, J Intern Med, 256, 183, 10.1111/j.1365-2796.2004.01388.x · DOI · Paper page
- American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorders, DSM-IV
- Klunk, 2004, Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009 · DOI · Paper page
- Schwarz, 2019, A comparison of partial volume correction techniques for measuring change in serial amyloid PET SUVR, J Alzheimers Dis, 67, 181, 10.3233/JAD-180749 · DOI · Paper page
- Ossenkoppele, 2019, Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease, Neurology, 92, e601, 10.1212/WNL.0000000000006875 · DOI · Paper page
- Lowe, 2018, Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia, Brain, 141, 271, 10.1093/brain/awx320 · DOI · Paper page
- Sintini, 2019, Longitudinal tau-PET uptake and atrophy in atypical Alzheimer’s disease, Neuroimage Clin, 23, 10.1016/j.nicl.2019.101823 · DOI · Paper page
- Harrison, 2019, Longitudinal tau accumulation and atrophy in aging and Alzheimer disease, Ann Neurol, 85, 229, 10.1002/ana.25406 · DOI · Paper page
- Vergallo, 2019, Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease, Alzheimers Dement, 15, 764, 10.1016/j.jalz.2019.03.009 · DOI · Paper page
- Zicha, 2022, Comparative analytical performance of multiple plasma Abeta42 and Abeta40 assays and their ability to predict positron emission tomography amyloid positivity, Alzheimers Dement, 10.1002/alz.12697 · DOI · Paper page
- Shen, 2021, Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status, Transl Psychiatry, 11, 585, 10.1038/s41398-021-01709-9 · DOI
- Meyer, 2022, Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults, Ann Neurol, 91, 548, 10.1002/ana.26308 · DOI · Paper page
- Palmqvist, An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease, Alzheimers Dement, 10.1002/alz.12751 · DOI · Paper page
- McGrath, 2022, Blood phosphorylated Tau 181 as a biomarker for amyloid burden on brain PET in cognitively healthy adults, J Alzheimers Dis, 87, 1517, 10.3233/JAD-215639 · DOI
- Jagust, 2021, Alzheimer’s disease neuroimaging I. Temporal dynamics of beta-amyloid accumulation in aging and Alzheimer’s disease, Neurology, 96, e1347, 10.1212/WNL.0000000000011524 · DOI · Paper page
- Tissot, 2022, Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET, EBioMedicine, 76, 10.1016/j.ebiom.2022.103837 · DOI · Paper page
- Soleimani-Meigooni, 2020, 18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases, Brain, 143, 3477, 10.1093/brain/awaa276 · DOI · Paper page
- Janelidze, 10 2022, Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease, Brain, 10.1093/brain/awac333 · DOI · Paper page
- Benedet, 2022, The accuracy and robustness of plasma biomarker models for amyloid PET positivity, Alzheimers Res Ther, 14, 26, 10.1186/s13195-021-00942-0 · DOI · Paper page
- Pascoal, 2020, 18F-MK-6240 PET for early and late detection of neurofibrillary tangles, Brain, 143, 2818, 10.1093/brain/awaa180 · DOI · Paper page
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationMachine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Karlsson, L., Vogel, J., Arvidsson, I., Åström, K., Strandberg, O., Seidlitz, J., Bethlehem, R. A. I., Stomrud, E., Ossenkoppele, R., Ashton, N. J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14600 · Cited by 43
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
Devanarayan, V., Charil, A., Horie, K., Doherty, T., Llano, D. A., Andreozzi, E., Sachdev, P., Ye, Y., Murali, L. K., Zhou, J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14411 · Cited by 19
Towards cascading genetic risk in Alzheimer’s disease
Altmann, A., Aksman, L. M., Oxtoby, N. P., Young, A. L., ADNI, Weiner, M., Aisen, P., Petersen, R., Weiner, M., Aisen, P., et al. (2024) · Brain · doi:10.1093/brain/awae176 · Cited by 18
Self-citation
Metadata
- Authors
- Jack, C. R., Wiste, H. J., Algeciras-Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., Graff-Radford, J., Boeve, B. F., Kantarci, K., Cogswell, P. M., Senjem, M. L., Gunter, J. L., Therneau, T. M., & Petersen, R. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-02-15
- Volume
- 146
- Issue
- 5
- Pages
- 2029-2044
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4320856239
- Cited by
- 147
- References
- 65
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- National Institutes of Health (R37 AG011378, RO1 AG041851, R01 AG056366, R01 NS097495, U01 AG06786, R01 AG034676)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.